Your browser doesn't support javascript.
loading
The European Biological Variation Study (EuBIVAS): Biological Variation Data for Coagulation Markers Estimated by a Bayesian Model.
Aarsand, Aasne K; Kristoffersen, Ann Helen; Sandberg, Sverre; Støve, Bård; Coskun, Abdurrahman; Fernandez-Calle, Pilar; Díaz-Garzón, Jorge; Guerra, Elena; Ceriotti, Ferruccio; Jonker, Niels; Røraas, Thomas; Carobene, Anna.
Afiliación
  • Aarsand AK; Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
  • Kristoffersen AH; Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, Bergen, Norway.
  • Sandberg S; Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
  • Støve B; Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, Bergen, Norway.
  • Coskun A; Department of Medical Biochemistry and Pharmacology, Haukeland University Hospital, Bergen, Norway.
  • Fernandez-Calle P; Norwegian Organization for Quality Improvement of Laboratory Examinations (Noklus), Haraldsplass Deaconess Hospital, Bergen, Norway.
  • Díaz-Garzón J; Department of Global Public Health and Primary Care, University of Bergen, Bergen, Norway.
  • Guerra E; Department of Mathematics, University of Bergen, Bergen, Norway.
  • Ceriotti F; Department of Medical Biochemistry, Acibadem Mehmet Ali Aydinlar University School of Medicine, Atasehir, Istanbul, Turkey.
  • Jonker N; Department of Laboratory Medicine, Hospital Universitario La Paz, Madrid, Spain.
  • Røraas T; Analytical Quality Commission of Spanish Society of Laboratory Medicine (SEQCML), Madrid, Spain.
  • Carobene A; Department of Laboratory Medicine, Hospital Universitario La Paz, Madrid, Spain.
Clin Chem ; 67(9): 1259-1270, 2021 09 01.
Article en En | MEDLINE | ID: mdl-34387652
BACKGROUND: For biological variation (BV) data to be safely used, data must be reliable and relevant to the population in which they are applied. We used samples from the European Biological Variation Study (EuBIVAS) to determine BV of coagulation markers by a Bayesian model robust to extreme observations and used the derived within-participant BV estimates [CVP(i)] to assess the applicability of the BV estimates in clinical practice. METHOD: Plasma samples were drawn from 92 healthy individuals for 10 consecutive weeks at 6 European laboratories and analyzed in duplicate for activated partial thromboplastin time (APTT), prothrombin time (PT), fibrinogen, D-dimer, antithrombin (AT), protein C, protein S free, and factor VIII (FVIII). A Bayesian model with Student t likelihoods for samples and replicates was applied to derive CVP(i) and predicted BV estimates with 95% credibility intervals. RESULTS: For all markers except D-dimer, CVP(i) were homogeneously distributed in the overall study population or in subgroups. Mean within-subject estimates (CVI) were <5% for APTT, PT, AT, and protein S free, <10% for protein C and FVIII, and <12% for fibrinogen. For APTT, protein C, and protein S free, estimates were significantly lower in men than in women ≤50 years. CONCLUSION: For most coagulation markers, a common CVI estimate for men and women is applicable, whereas for APTT, protein C, and protein S free, sex-specific reference change values should be applied. The use of a Bayesian model to deliver individual CVP(i) allows for improved interpretation and application of the data.
Asunto(s)
Palabras clave
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrinógeno / Proteína C Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Clin Chem Asunto de la revista: QUIMICA CLINICA Año: 2021 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Reino Unido
Texto completo
Añadir a Mi BVS
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Fibrinógeno / Proteína C Tipo de estudio: Prognostic_studies Límite: Female / Humans / Male Idioma: En Revista: Clin Chem Asunto de la revista: QUIMICA CLINICA Año: 2021 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Reino Unido